Cardiac Surgeries Segment to Dominate Asia-Pacific Autotransfusion Devices Market during 2019–2028
According to The Insight Partners market research study on “Asia-Pacific Autotransfusion Devices Market to 2028 – COVID-19 Impact and Regional Analysis and Forecast by Type, Application, and End User,” is expected to reach US$ 349.09 million by 2028 from US$ 250.35 million in 2021. The market is estimated to grow at a CAGR of 4.9% from 2021 to 2028. Elevated healthcare expenditure in emerging economies is the major factor driving the growth of the Asia-Pacific autotransfusion devices market. However, risks associated with autotransfusion may hinder the growth of Asia-Pacific autotransfusion devices market. The report provides trends prevailing in the Asia-Pacific autotransfusion devices market along with the drivers and restraints pertaining to the market growth.
The Asia-Pacific autotransfusion devices market is segmented into type, application, end user, and country. The Asia-Pacific autotransfusion devices market, by type, is segmented into products and accessories. In 2021, the accessories segment held the largest share Asia-Pacific autotransfusion devices market. The products is further sub-segmented into intraoperative autotransfusion systems, postoperative autotransfusion systems, and dual-mode autotransfusion systems. In 2021, the intraoperative autotransfusion systems segment held the largest share Asia-Pacific autotransfusion devices market. The Asia-Pacific autotransfusion devices market, by application, is segmented into cardiac surgeries, orthopedic surgeries, organ transplantation, trauma procedures, and others. The cardiac surgeries segment held the largest share of the market in 2021. Based on end user, the Asia-Pacific autotransfusion devices market is segmented hospitals, specialty clinics, and ambulatory surgical centers. The hospitals segment held the largest share of the market in 2021. Similarly, based on country, the Asia-Pacific autotransfusion devices market is segmented into China, Japan, India, South Korea, Australia, and the rest of Asia-Pacific. Japan contributed a substantial share in 2021.
BD, Braile Biomedica, Fresenius SE & Co. KGaA, Haemonetics Corporation, LivaNova PLC, Medtronic, Redax S.p.A., SARSTEDT AG and Co. KG, Teleflex Incorporated, and Zimmer Biomet are among the leading companies in the Asia-Pacific autotransfusion devices market. The companies are focused on adopting organic growth strategies such as product launches and expansions to sustain their position in the dynamic market. For instance, in 2020, Teleflex Incorporated initiated Class 2 Device Recall for its autotransfusion device PleurEvac, as directed by U.S Food and Drug Administration (USFDA). The product was recalled due to Potential for sterile packaging to be compromised.
Contact Us
Phone: +1-646-491-9876
Email Id: sales@theinsightpartners.com